Literature DB >> 25116897

Contemporary patterns of discharge aspirin dosing after acute myocardial infarction in the United States: results from the National Cardiovascular Data Registry (NCDR).

Hurst M Hall1, James A de Lemos1, Jonathan R Enriquez1, Darren K McGuire1, S Andrew Peng1, Karen P Alexander1, Matthew T Roe1, Nihar Desai1, Stephen D Wiviott1, Sandeep R Das2.   

Abstract

BACKGROUND: Accumulated data suggest that low-dose aspirin after myocardial infarction (MI) may offer similar efficacy to higher dose aspirin with reduced risk of bleeding. Few data are available on contemporary aspirin dosing patterns after MI in the United States METHODS AND
RESULTS: Aspirin dosing from 221 199 patients with MI (40.2% ST-segment-elevation MI) from 525 US hospitals enrolled in the National Cardiovascular Data Registry's (NCDR's) Acute Coronary Treatment and Intervention Outcomes Network Registry-Get with the Guidelines were described, overall and in clinically relevant subgroups. High-dose aspirin was defined as 325 mg and low dose as 81 mg. Between January 2007 and March 2011, 60.9% of patients with acute MI were discharged on high-dose aspirin, 35.6% on low-dose aspirin, and 3.5% on other doses. High-dose aspirin was prescribed at discharge to 73.0% of patients treated with percutaneous coronary intervention and 44.6% of patients managed medically. Among 9075 patients discharged on aspirin, thienopyridine, and warfarin, 44.0% were prescribed high-dose aspirin. Patients with an in-hospital major bleeding event were also frequently discharged on high-dose aspirin (56.7%). A 25-fold variation in the proportion prescribed high-dose aspirin at discharge was observed across participating centers.
CONCLUSIONS: Most US patients with MI continue to be discharged on high-dose aspirin. Although aspirin dosing after percutaneous coronary intervention largely reflected prevailing guidelines before 2012, high-dose aspirin was prescribed with similar frequency in medically managed patients and to those in categories expected to be at high risk for bleeding. Wide variability in the proportional use of high-dose aspirin across centers suggests significant influence from local practice habits and uncertainty about appropriate aspirin dosing.
© 2014 American Heart Association, Inc.

Entities:  

Keywords:  acute coronary syndrome; aspirin

Mesh:

Substances:

Year:  2014        PMID: 25116897     DOI: 10.1161/CIRCOUTCOMES.113.000822

Source DB:  PubMed          Journal:  Circ Cardiovasc Qual Outcomes        ISSN: 1941-7713


  12 in total

1.  Considerations in the evaluation and determination of minimal risk in pragmatic clinical trials.

Authors:  John D Lantos; David Wendler; Edward Septimus; Sarita Wahba; Rosemary Madigan; Geraldine Bliss
Journal:  Clin Trials       Date:  2015-09-15       Impact factor: 2.486

Review 2.  Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association.

Authors:  Emelia J Benjamin; Michael J Blaha; Stephanie E Chiuve; Mary Cushman; Sandeep R Das; Rajat Deo; Sarah D de Ferranti; James Floyd; Myriam Fornage; Cathleen Gillespie; Carmen R Isasi; Monik C Jiménez; Lori Chaffin Jordan; Suzanne E Judd; Daniel Lackland; Judith H Lichtman; Lynda Lisabeth; Simin Liu; Chris T Longenecker; Rachel H Mackey; Kunihiro Matsushita; Dariush Mozaffarian; Michael E Mussolino; Khurram Nasir; Robert W Neumar; Latha Palaniappan; Dilip K Pandey; Ravi R Thiagarajan; Mathew J Reeves; Matthew Ritchey; Carlos J Rodriguez; Gregory A Roth; Wayne D Rosamond; Comilla Sasson; Amytis Towfighi; Connie W Tsao; Melanie B Turner; Salim S Virani; Jenifer H Voeks; Joshua Z Willey; John T Wilkins; Jason Hy Wu; Heather M Alger; Sally S Wong; Paul Muntner
Journal:  Circulation       Date:  2017-01-25       Impact factor: 29.690

3.  Relation of Habitual Chocolate Consumption to Arterial Stiffness in a Community-Based Sample: Preliminary Findings.

Authors:  Georgina E Crichton; Merrill F Elias; Ala'a Alkerwi; Saverio Stranges; Walter P Abhayaratna
Journal:  Pulse (Basel)       Date:  2016-05-03

4.  Cardiovascular events after discontinuation of low-dose aspirin.

Authors:  Manan Pareek; Steen D Kristensen; Erik L Grove
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

Review 5.  The ADAPTABLE Trial and Aspirin Dosing in Secondary Prevention for Patients with Coronary Artery Disease.

Authors:  Abigail Johnston; W Schuyler Jones; Adrian F Hernandez
Journal:  Curr Cardiol Rep       Date:  2016-08       Impact factor: 2.931

Review 6.  Enhancing participation in cardiac rehabilitation: Focus on underserved populations.

Authors:  Philip A Ades; Sherrie Khadanga; Patrick D Savage; Diann E Gaalema
Journal:  Prog Cardiovasc Dis       Date:  2022-01-31       Impact factor: 11.278

7.  Prospective Evaluation of Genetic Variation in Platelet Endothelial Aggregation Receptor 1 Reveals Aspirin-Dependent Effects on Platelet Aggregation Pathways.

Authors:  J D Backman; L M Yerges-Armstrong; R B Horenstein; S Newcomer; S Shaub; M Morrisey; P Donnelly; M Drolet; K Tanner; M A Pavlovich; J R O'Connell; B D Mitchell; J P Lewis
Journal:  Clin Transl Sci       Date:  2017-01-11       Impact factor: 4.689

8.  Systems Pharmacogenomics Finds RUNX1 Is an Aspirin-Responsive Transcription Factor Linked to Cardiovascular Disease and Colon Cancer.

Authors:  Deepak Voora; A Koneti Rao; Gauthami S Jalagadugula; Rachel Myers; Emily Harris; Thomas L Ortel; Geoffrey S Ginsburg
Journal:  EBioMedicine       Date:  2016-08-14       Impact factor: 8.143

Review 9.  PA32540 for the secondary prevention of cardiovascular disease in patients at risk for aspirin-associated gastric ulcers.

Authors:  Danielle Duffy; Bridget Rooney; Suzanne Adams; David J Whellan
Journal:  Expert Rev Cardiovasc Ther       Date:  2014-10-10

10.  Validation of a claims-based algorithm identifying eligible study subjects in the ADAPTABLE pragmatic clinical trial.

Authors:  Ezra Fishman; John Barron; Jade Dinh; W Schuyler Jones; Amanda Marshall; Rebecca Merkh; Holly Robertson; Kevin Haynes
Journal:  Contemp Clin Trials Commun       Date:  2018-11-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.